Search research articles
Contact Us
Filters
Showing results (151-160 of 191) with videos related to
Page
of 20
Sort By:
Journal of Viral Hepatitis
|
May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
Eric Lawitz, Edward Gane, Jordan J Feld, et al.
The Journal of Clinical Investigation
|
January 9, 2018
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
Laura Rivino, Nina Le Bert, Upkar S Gill, et al.
The International Journal on Drug Policy
|
June 28, 2024
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Pantelis Samartsidis, Ross J Harris, John Dillon, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
July 5, 2024
Pilot postal birth cohort hepatitis C virus screening in UK primary care: HepCAPP study
Ruth Simmons, Annabel A Powell, Samreen Ijaz, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
François M J Lamoury, Angelica Soker, Danica Martinez, et al.
Gastroenterology
|
November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial
Stefan Zeuzem, Thomas Berg, Edward Gane, et al.
The International Journal on Drug Policy
|
June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Håvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
Journal of Gastroenterology and Hepatology
|
March 18, 2011
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
Keyur Patel, Alexander J Thompson, Wan-Long Chuang, et al.
The Lancet Regional Health. Europe
|
January 6, 2025
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Health Technology Assessment (Winchester, England)
|
February 3, 2026
The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 191) with videos related to
Sort By:
Page
of 20
Journal of Viral Hepatitis
|
May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
Eric Lawitz, Edward Gane, Jordan J Feld, et al.
The Journal of Clinical Investigation
|
January 9, 2018
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
Laura Rivino, Nina Le Bert, Upkar S Gill, et al.
The International Journal on Drug Policy
|
June 28, 2024
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Pantelis Samartsidis, Ross J Harris, John Dillon, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
July 5, 2024
Pilot postal birth cohort hepatitis C virus screening in UK primary care: HepCAPP study
Ruth Simmons, Annabel A Powell, Samreen Ijaz, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
François M J Lamoury, Angelica Soker, Danica Martinez, et al.
Gastroenterology
|
November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial
Stefan Zeuzem, Thomas Berg, Edward Gane, et al.
The International Journal on Drug Policy
|
June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Håvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
Journal of Gastroenterology and Hepatology
|
March 18, 2011
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
Keyur Patel, Alexander J Thompson, Wan-Long Chuang, et al.
The Lancet Regional Health. Europe
|
January 6, 2025
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Health Technology Assessment (Winchester, England)
|
February 3, 2026
The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling
Zoe Ward, Ruth Simmons, Hannah Fraser, et al.
Page
of 20